Does not appear to be any update for the sepsis or Covid/Flu A/Flu B space in the Report. That concerns me, as the life sciences update seems to be more geared towards to acquisitions rather than development of new tests.
EDIT: "Cessation and realignment of resources from existing clinical developments (COVID-19, Multiplex, PCT) to assay development, due to regulatory and market conditions."
Ann: Company Update, page-2
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
0.001(4.55%) |
Mkt cap ! $56.67M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.3¢ | 2.2¢ | $7.175K | 316.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 2237568 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 592176 | 5 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.3¢ |
Change
0.001 ( 4.55 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.3¢ | 2.2¢ | 1213592 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| ADO (ASX) Chart |